Keyword Index
Browse for an article via relevant keywords across our entire electronic archive
Search results for: M
Results 81 - 90 of 606 shown below
MAPK pathway
W Zuidervaart, F van Nieuwpoort, M Stark, R Dijkman, L Packer, A-M Borgstein, S Pavey, P van der Velden, C Out, M J Jager, N K Hayward and N A Gruis
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
doi:10.1038/sj.bjc.6602598
Abstract | Full article | PDF
mapping
N Miura, N Onuki, A Rathi, A Virmani, S Nakamoto, Y Kishimoto, Y Murawaki, H Kawasaki, J Hasegawa, M Oshimura, W D Travis and A F Gazdar
hTR repressor-related gene on human chromosome 10p15.1
doi:10.1054/bjoc.2001.2121
margins
H K Tan, P Saulnier, A Auperin, L Lacroix, O Casiraghi, F Janot, P Fouret and S Temam
Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas
advance online publication, 2008-07-01 00:00:00.000;
doi:10.1038/sj.bjc.6604478
Abstract | Full article | PDF
marimastat
S R Bramhall, M T Hallissey, J Whiting, J Scholefield, G Tierney, R C Stuart, R E Hawkins, P McCulloch, T Maughan, P D Brown, M Baillet and J W L Fielding
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
doi:10.1038/sj.bjc.6600310
Abstract | Full article | PDF
-
S R Bramhall, J Schulz, J Nemunaitis, P D Brown, M Baillet and J A C Buckels
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
doi:10.1038/sj.bjc.6600446
Abstract | Full article | PDF
-
J N Primrose, H Bleiberg, F Daniel, S Van Belle, M Seymour, M Baillet, K Barker, A Berrington and K P Lynch
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
doi:10.1038/sj.bjc.6690079
-
S A Watson, T M Morris, H M Collins, L J Bawden, K Hawkins and E A Bone
Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA
doi:10.1038/sj.bjc.6690645
-
J D Evans, A Stark, C D Johnson, F Daniel, J Carmichael, J Buckels, C W Imrie, P Brown and J P Neoptolemos
A phase II trial of marimastat in advanced pancreatic cancer
doi:10.1054/bjoc.2001.2168
marine natural compounds
E Erba, M Serafini, G Gaipa, G Tognon, S Marchini, N Celli, D Rotilio, M Broggini, J Jimeno, G T Faircloth, A Biondi and M D'Incalci
Effect of Aplidin in acute lymphoblastic leukaemia cells
doi:10.1038/sj.bjc.6601130
Abstract | Full article | PDF
marker
P H Watson, S K Chia, C C Wykoff, C Han, R D Leek, W S Sly, K C Gatter, P Ratcliffe and A L Harris
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma
doi:10.1038/sj.bjc.6600796
Abstract | Full article | PDF
-
R D Riley, K R Abrams, A J Sutton, P C Lambert, D R Jones, D Heney and S A Burchill
Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future
doi:10.1038/sj.bjc.6600886
Abstract | Full article | PDF
-
S Staibano, F Merolla, D Testa, R Iovine, M Mascolo, V Guarino, M D Castellone, M Di Benedetto, V Galli, S Motta, R M Melillo, G De Rosa, M Santoro and A Celetti
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome
advance online publication, 2007-11-06 00:00:00.000;
doi:10.1038/sj.bjc.6604070
Abstract | Full article | PDF
-
H Uemura, Y Nakagawa, K Yoshida, S Saga, K Yoshikawa, Y Hirao and E Oosterwijk
MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
doi:10.1038/sj.bjc.6690757
marker expression
K A Landers, H Samaratunga, L Teng, M Buck, M J Burger, B Scells, M F Lavin and R A Gardiner
Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
advance online publication, 2008-07-22 00:00:00.000;
doi:10.1038/sj.bjc.6604486
Abstract | Full article | PDF
-
E A Dublin, R R Millis, P Smith and L G Bobrow
Minimal breast cancer: evaluation of histology and biological marker expression
doi:10.1038/sj.bjc.6690570
marker genes
B Weigelt, A J Bosma, A A M Hart, S Rodenhuis and L J van 't Veer
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
doi:10.1038/sj.bjc.6600868
Abstract | Full article | PDF
markers
M McCallum, C Baker, K Gillespie, B Cohen, H Stewart, R Leonard, D Cameron, R Leake, J Paxton, A Robertson, C Purdie, A Gould and M Steel
A prognostic index for operable, node-negative breast cancer
advance online publication, 2004-04-27 00:00:00.000;
doi:10.1038/sj.bjc.6601826
Abstract | Full article | PDF
-
M Wager, P Menei, J Guilhot, P Levillain, S Michalak, B Bataille, J-L Blanc, F Lapierre, P Rigoard, S Milin, F Duthe, D Bonneau, C-J Larsen and L Karayan-Tapon
Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study
advance online publication, 2008-05-27 00:00:00.000;
doi:10.1038/sj.bjc.6604378
Abstract | Full article | PDF
-
T J Phesse and A R Clarke
Normal stem cells in cancer prone epithelial tissues
advance online publication, 2009-01-06 00:00:00.000;
doi:10.1038/sj.bjc.6604850
Abstract | Full article | PDF
-
Z Popov, S Gil-Diez de Medina, M-A Lefrere-Belda, A Hoznek, S Bastuji-Garin, C C Abbou, J P Thiery, F Radvanyi and D K Chopin
Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information
doi:10.1054/bjoc.2000.1233
marketing approval
G Apolone, R Joppi, V Bertele' and S Garattini
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures
advance online publication, 2005-08-23 00:00:00.000;
doi:10.1038/sj.bjc.6602750
Abstract | Full article | PDF
